Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 2/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28770944 | 0.88 | THRB (0.42) | KMT2AMEN1POLBTHRBALDH1A1 | |
| SCHEMBL4111419 | 0.87 | KMT2A (0.39) | KMT2AMEN1POLBCTDSP1CTSC | |
| SCHEMBL4103811 | 0.85 | KMT2A (0.41) | KMT2AMEN1POLBANO1THRB | |
| SCHEMBL4097141 | 0.84 | KMT2A (0.39) | KMT2AMEN1POLBANO1THRB | |
| SCHEMBL13964896 | 0.84 | KMT2A (0.40) | KMT2AMEN1POLBANO1THRB | |
| SCHEMBL4097043 | 0.83 | KMT2A (0.50) | KMT2AMEN1POLBANO1ALDH1A1 | |
| SCHEMBL14625098 | 0.83 | KMT2A (0.40) | KMT2AMEN1POLBCTDSP1CTSC | |
| SCHEMBL4101390 | 0.82 | MEN1 (0.41) | KMT2AMEN1POLBCTDSP1THRB | |
| SCHEMBL13964894 | 0.82 | KMT2A (0.51) | KMT2AMEN1POLBANO1ALDH1A1 | |
| SCHEMBL4106921 | 0.80 | CNR2 (0.39) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| EP-1910328-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007001225-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS. | ASTRAZENECA (SE) | 2007-01-04 | — | — | WO | claimed |
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| EP-1910328-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007001225-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS ALPHA 7 NICOTINIC RECEPTOR MODULATORS. | ASTRAZENECA (SE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012127-A1 | Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators | CHRNA7, CHRNA1, CHRNA5 | KMT2A 1400/4885MEN1 2692/4885POLB 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.